Treatment of stage III-IV non-small-cell lung carcinoma with vinorelbine in combination with ifosfamide plus MESNA: A study by the Southern Italy Oncology Group (GOIM)

Vittorio Gebbia, Domenico Galetta, Evaristo Majello, Roberto Valenza, Giuseppe Colucci, Nicolò Gebbia

Research output: Contribution to journalArticle

Abstract

Thirty-five patients affected by stage III-IV non-small-cell lung carcinomas were treated with ifosfamide 3 gr/m2 plus MESNA as uroprotector on day 1 and vinorelbine 25 mg/m2 i.v. bolus on day 1 and 8. This cycle was repeated every 21 days. Over a total of 35 evaluable patients, the overall response rate was 34% (95% CL 18-54%). One patient experienced a complete response with a duration of 7.2+ months, and 11 patients a partial response with a mean duration of 5.9+ months. Seven patients had no change and 16 improved. The overall survival was 7.6+ months. Over a total of 145 cycles, the most frequent toxicity was myelosuppression, but grade 3 leukopenia and grade 2 thrombocytopenia were seen only in 14% and 9% of cases, respectively. Only one patient suffered grade 4 leukopenia. Gastrointestinal toxicity was minimal; only five patients (14%) complained of grade 3 vomiting. This combination regimen can be safely given on an outpatient regimen, but it is relatively active in advanced non-small-cell lung cancer. However, it should be noted that >50% of the patients in this series had a performance status of 50% were older than 65 years.

Original languageEnglish
Pages (from-to)278-280
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume19
Issue number3
DOIs
Publication statusPublished - Jun 1996

Keywords

  • Chemotherapy
  • Ifosfamide
  • Metastasis
  • Non-small-cell lung cancer
  • Vinorelbine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Treatment of stage III-IV non-small-cell lung carcinoma with vinorelbine in combination with ifosfamide plus MESNA: A study by the Southern Italy Oncology Group (GOIM)'. Together they form a unique fingerprint.

  • Cite this